Kathleen Goin Sells 4,302 Shares of Palvella Therapeutics (NASDAQ:PVLA) Stock

Palvella Therapeutics, Inc. (NASDAQ:PVLA) COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $97.63, for a total value of $420,004.26. The sale was disclosed in a filing with the SEC, which is available through this link.

Kathleen Goin also recently made the following trade(s):

• On Wednesday, December 17th, Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock. The stock was sold at an average price of $96.47, for a total value of $415,013.94.
• On Wednesday, November 19th, Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock. The shares were sold at an average price of $86.23, for a total value of $370,961.46.

Palvella Therapeutics Stock Down 7.4%

Shares of NASDAQ:PVLA opened at $85.30 on Friday. The business’s 50 day moving average is $97.37 and its 200 day moving average is $70.70. Palvella Therapeutics, Inc. has a 12-month low of $12.10 and a 12-month high of $114.69. The stock has a market cap of $1.01 billion, a price-to-earnings ratio of -32.43 and a beta of -0.16.

Palvella Therapeutics (NASDAQ:PVLA) last issued its quarterly earnings data on Monday, November 10th. The company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.18). As a group, equities research analysts expect that Palvella Therapeutics, Inc. will post -3.69 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on PVLA shares. UBS Group reaffirmed a “buy” rating and issued a $143.00 price objective on shares of Palvella Therapeutics in a research report on Monday, December 15th. TD Cowen reaffirmed a “buy” rating on shares of Palvella Therapeutics in a report on Tuesday, December 16th. Truist Financial increased their price target on Palvella Therapeutics from $105.00 to $190.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Weiss Ratings reiterated a “sell (d)” rating on shares of Palvella Therapeutics in a report on Monday, December 29th. Finally, Oppenheimer restated an “outperform” rating and issued a $200.00 price objective on shares of Palvella Therapeutics in a research note on Monday, December 15th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $158.69.

Hedge Funds Weigh In On Palvella Therapeutics

Several institutional investors have recently bought and sold shares of the company. Suvretta Capital Management LLC increased its position in Palvella Therapeutics by 15.1% in the third quarter. Suvretta Capital Management LLC now owns 822,400 shares of the company’s stock worth $51,556,000 after buying an additional 107,937 shares during the last quarter. Frazier Life Sciences Management L.P. grew its stake in shares of Palvella Therapeutics by 4.7% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 722,400 shares of the company’s stock worth $16,283,000 after acquiring an additional 32,388 shares during the period. First Light Asset Management LLC purchased a new stake in Palvella Therapeutics in the 3rd quarter worth about $33,949,000. Vanguard Group Inc. raised its stake in Palvella Therapeutics by 202.0% in the 3rd quarter. Vanguard Group Inc. now owns 494,656 shares of the company’s stock valued at $31,010,000 after acquiring an additional 330,847 shares during the period. Finally, Federated Hermes Inc. bought a new stake in Palvella Therapeutics in the 3rd quarter valued at about $21,255,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.